Turnstone Biologics

Oncolytic viral immunotherapy

Also Clin1 melanomas, combo Clin0 solid tumors; TIDAL-02 Clin0 solid tumors

Turnstone Biologics is creating next-generation tumor infiltrating lymphocyte therapies, selecting the most tumor-reactive T-cells to treat solid tumors. They have also paired this strategy with viral immunotherapy for improved efficiency and effectiveness. By exploiting the tumor microenvironment and stimulating an immune response, Turnstone's therapies not only eradicate cancer cells but also enhance the body's natural ability to fight the disease. This novel approach holds immense potential for transforming cancer treatment paradigms and improving patient outcomes. Turnstone is made up of experts in tumor infiltrating lymphocytes, cell therapies, tumor immunology, immunity, and oncolytic viruses and has collaborations with the NIH and Moffitt Cancer Center.